Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Heart failure with "mid-range" ejection fraction: a new clinical entity?]

Peter Rickenbacher1

  • 11 Abteilung für Kardiologie, Medizinische Universitätsklinik, Kantonsspital Baselland, Bruderholz.

Therapeutische Umschau. Revue Therapeutique
|August 28, 2018
PubMed
Summary

Heart failure with mid-range ejection fraction (HFmrEF) is a distinct condition affecting 10-20% of heart failure patients. This group exhibits intermediate characteristics and poor outcomes, potentially representing a transitional stage between other heart failure types.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Insulin-Treated Compared to Non-Insulin-Treated Diabetes Mellitus on Outcome of Percutaneous Coronary Intervention with Drug-Coated Balloons versus Drug-Eluting Stents in De Novo Coronary Artery Disease: The Randomized BASKET-SMALL 2 Trial.

Journal of cardiovascular development and disease·2023
Same author

Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2.

Circulation. Cardiovascular interventions·2022
Same author

Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents: The BASKET-SMALL 2 Trial.

JACC. Cardiovascular interventions·2021
Same author

Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial.

Lancet (London, England)·2020
Same author

Long-Term Results After Drug-Eluting Versus Bare-Metal Stent Implantation in Saphenous Vein Grafts: Randomized Controlled Trial.

Journal of the American Heart Association·2020
Same author

Prognostic Significance of Longitudinal Clinical Congestion Pattern in Chronic Heart Failure: Insights From TIME-CHF Trial.

The American journal of medicine·2019

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Heart Failure Research

Background:

  • Heart failure (HF) is categorized by ejection fraction (EF) into reduced (HFrEF) and preserved (HFpEF) types.
  • A significant patient group presents with intermediate EF, lacking clear classification and distinct management strategies.

Purpose of the Study:

  • To define and characterize heart failure with mid-range ejection fraction (HFmrEF) as a new clinical entity.
  • To compare HFmrEF characteristics, etiology, and outcomes with HFrEF and HFpEF populations.

Main Methods:

  • Literature review and analysis of existing epidemiological and clinical data on HF patients.
  • Comparison of clinical features, etiological factors (e.g., coronary disease), and prognostic data across HFmrEF, HFrEF, and HFpEF groups.

Related Experiment Videos

Main Results:

  • HFmrEF is defined by HF symptoms, EF of 40-49%, elevated natriuretic peptides, and structural heart disease.
  • Prevalence of HFmrEF is estimated at 10-20% of all HF patients.
  • HFmrEF patients exhibit intermediate clinical profiles, with coronary disease prevalence similar to HFrEF.
  • Outcomes for HFmrEF are poor, comparable to HFrEF and HFpEF.

Conclusions:

  • HFmrEF represents a distinct clinical entity within the heart failure spectrum.
  • This group often serves as a transitional stage between HFrEF and HFpEF.
  • Preliminary evidence suggests potential benefits from HFrEF-indicated therapies in HFmrEF patients, warranting further investigation.